secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2022-06-10T23:59:59+00:00
Accession:  0001193125-22-172060
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 2.03, 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

CFO/COO and director Christopher Lowe resigns; June Bray appointed director; Monohon named PFO
--------------------------------------------------------------------------------

- Christopher Lowe resigned as board member (June 8) and as CFO/COO (effective June 10); separation includes $354,750 cash severance and equity acceleration.
- June Bray appointed as Class III director; receives initial option for 54,000 shares at $3.20, vesting over 3 years.
- Ted Monohon, current CAO and VP Finance, designated as principal financial officer; no change in compensation.
- Sublease with ICON Clinical Research for 601 Gateway Blvd, SF: term June 18, 2022 to Nov 30, 2023, optional extension; rent $16,692-$17,206/mo.
- Annual meeting: elected Lowe and Senner as directors, ratified BDO as auditor, approved say-on-pay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/0001193125-22-172060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522172060/d331287d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-172060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer